The company anticipates a first closing of around EUR 60 million in brief.
Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M.
The round was led by two of the most experienced life science investors in Europe, LSP (Netherlands) and Ventech (France).
Ysios Capital Partners will be raising €65 million for their first fund, Ysios BioFund I.
Subscribe to our weekly newsletter for the latest updates on life sciences investments.